Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Infergen
Synonyms :
Interferon alfacon-1
Class :
Interferons
Brand Name :
Infergen
Synonyms :
Interferon alfacon-1
Class :
Interferons
Dosage Forms & StrengthsÂ
Single-use- vialsÂ
9mcg/0.3mlÂ
15mcg/0.5mlÂ
Monotherapy
9mcg subcutaneous injection thrice a week for 24 weeks
For patients who responded to prior interferon therapy but did not respond or relapse after it was stopped, a 15 mcg subcutaneous injection thrice a week for up to 48 weeks is the recommended dose of interferon alfacon-1 monotherapy
Combination therapy
15mcg subcutaneous injection of interferon alfacon-1 once daily along with 1000- 1200mg ribavirin orally in two doses upto 48 weeks
Note: In patients with Crcl<50ml/min. ribavirin is not recommended
Dosage Forms & StrengthsÂ
Safety and efficacy studies are not establishedÂ
Refer to adult dosingÂ
the risk of adverse effects may be increased
the risk of bleeding may be increased
the rate of metabolism of acenocoumarol may be reduced
the rate of metabolism of acetaminophen may be reduced
the risk of infection may be increased
the rate of metabolism of agomelatine may be reduced
the risk of adverse effects may be increased
the rate of metabolism of aminophylline may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of infection may be increased
the risk of adverse effects may be increased
the risk of thrombocytopenia and neutropenia may be increased
the rate of metabolism of betaxolol may be reduced
the risk of bleeding may be increased
the risk of bleeding may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
Actions and spectrum:Â
Type I interferon receptors like IFNAR1 and IFNAR2c are bound by interferon alpha, and these receptors activate and dimerize two Jak Janus kinases and tyrosine kinases namely Jak1 and Tyk2. These phosphorylate receptors and transphosphorylate themselves.
Following their binding to Stat1 and 2, which are transcription activators and signal transducer, the phosphorylated INFAR receptors activate and dimerize many (about 100) antiviral and immunomodulatory proteins. Compared to interferon beta, interferon alpha binds to interferon receptors of type I less stably.
Gene transcription, cellular growth inhibition, state modification of cellular differentiation, oncogene expression interference, modification of cell surface antigen expression, increased macrophage phagocytic activity, and increased lymphocyte cytotoxicity for target cells are among the actions that follow.Â
Frequency not definedÂ
NervousnessÂ
HeadacheÂ
IrritabilityÂ
Back painÂ
DiarrheaÂ
Weight lossÂ
Muscle painÂ
TirednessÂ
NumbnessÂ
Changes in moodÂ
Depression Â
Alopecia Â
Black Box Warning Â
To be administered in the presence of a qualified doctorÂ
Contraindication/Caution:Â
Contraindication to interferon alfacon-1:Â
Known hypersensitivityÂ
Hepatic decompensationÂ
Autoimmune hepatitisÂ
AngioedemaÂ
Anaphylaxis to interferon alfaÂ
bronchoconstrictionÂ
Contraindication to ribavarin:Â
Hypersensitivity Â
Pregnant populationÂ
ThalassemiaÂ
Sickle cell anemiaÂ
CrCl< 50ml/minÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: CÂ
Lactation:Â Â
Data about the excretion of interferon alfacon-1 into human milk is not known. Hence, caution is recommended.Â
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Interferon alfacon-1 is a synthetic, non-naturally existing interferon of type I.Â
Pharmacodynamics:Â
It increases the effectiveness of peptides derived from viral antigens by upregulating the expression of MHC I proteins. This improves the macrophage’s suitability for CTL-mediated killing by boosting the activation of CD8+ T cells, which are the progenitors of cytotoxic T lymphocytes (CTLs). In addition, interferon alpha stimulates the production of multiple essential antiviral mediators, such as protein kinase R and 2′-5′ oligoadenylate synthetase (2′-5′ A synthetase).Â
Pharmacokinetics:Â Â
Pharmacokinetic study is not evaluated in patients suffering from chronic hepatitis C infection. Â
Administration:Â
INFERGEN (interferon alfa con-1) may be allowed to come to room temperature right before injection.Â
Before administration, parenteral drug products should be checked clearly for particulate matter and discoloration; if either is seen, the vial should not be used.Â
Patient information leafletÂ
Generic Name: interferon alfacon-1Â Â
Why do we use interferon alfacon-1?Â
Interferon alfacon-1, recommended for the treating chronic hepatitis C in patients suffering with compensated liver disease who are 18 years of age or older. This recommendation is supported by clinical trials that evaluated interferon alfacon-1 as monotherapy before combination therapy became the norm and by a single trial that assessed interferon alfacon-1 in combination with ribavirin in patients who did not respond to prior pegylated interferon and ribavirin treatment.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
